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Background: Coronary artery disease remains the dominant cause of mortality in developed countries. While
platelets have been recognized to play a pivotal role in atherothrombosis, the ideal antiplatelet regime after
coronary artery surgery remains elusive.
The evolution of CABG has presently moved beyond technical improvements to involve modulation of
pharmacologic management designed to improve patient outcomes. The aim of this trial will be to test the
hypothesis that the addition of clopidogrel to patients with documented postoperative aspirin resistance will
reduce the incidence of major cardiovascular events.
Methods: Patients scheduled for isolated coronary artery surgery will be eligible for the study. Patients in whom
postoperative multiple electrode aggregometry documents aspirin resistance will be randomized into two groups.
The control group will receive 300 mg of aspirin. The dual antiplatelet group will receive 75 mg of clopidogrel in
addition to 300 mg of aspirin. Patients will be followed for 6 months. Major adverse cardiac and cerebrovascular
events (death from any cause, myocardial infarction, stroke, hospitalization due to cardiovascular pathology) as well
as bleeding events will be recorded.
Discussion: This will be the first trial that will specifically address the issue of dual antiplatelet therapy in patients
undergoing coronary artery surgery who have been found to be aspirin resistant. In the event that the addition of
clopidogrel proves to be beneficial in this subset of surgical patients, this study could significantly impact their
future antiplatelet management.
This randomized controlled trial has been registered at the ClinicalTrials.gov website (Identifier NCT01159639).
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Coronary artery disease is a health care issue of epidemic
proportions, and has a profound impact on resource
utilization. A quiescent atherosclerotic lesion may follow
the course of progressive luminal encroachment, or suc-
cumb to an acute thrombotic event. Reduced de novo
collagen synthesis and increased extracellular matrix me-
tabolism contribute to weakening of the fibrous cap [1].
Platelet aggregation is a crucial component of this* Correspondence: hgasparovic@gmail.com
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distribution, and reproduction in any mediumprocess. Coronary artery bypass grafting (CABG) remains
the best management option for patients with severe
multi-vessel coronary artery disease [2]. It has been sub-
jected to an unparalleled level of scientific scrutiny. The
continuous trend toward improving patient outcomes fol-
lowing CABG stems from refinement of the technical
aspects of the procedure, as well as optimization of the ad-
juvant pharmacologic therapy.Antiplatelet management following CABG
Platelet inhibition is paramount in the management of cor-
onary artery disease. Antiplatelet drugs reduce mortalitytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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with a wide variety of vascular occlusive pathologies [3].
Their beneficial effects must be, however, balanced against
the associated risk of bleeding. Acetylsalicylic acid (ASA)
is currently recommended after CABG in order to im-
prove long-term graft patency [4]. The recommended
doses range from 150 to 325 mg, with a trend towards
clinical benefit when higher doses are utilized within the
first year [4]. There is no compelling evidence to support
the superiority of clopidogrel to ASA monotherapy in op-
timizing graft patency following CABG [4]. The mechan-
isms of action of thienopyridines and ASA differ, allowing
for a cumulative anti-aggregative effect [3,5]. ASA irre-
versibly suppresses cyclooxygenase-1 activity thereby re-
ducing thromboxane A2 production, whereas clopidogrel
acts on the P2Y12 adenosine diphosphate (ADP) receptor
to inhibit ADP-mediated platelet aggregation [6,7]. While
dual antiplatelet therapy offers a reduction in atheroscler-
otic events in patients undergoing percutaneous coronary
interventions, this benefit has not been reliably repro-
duced in other clinical settings [7,8].
Individual variability to antiplatelet agents
The incidence of interpatient variability to antiplatelet
drugs depends upon the laboratory evaluation used to
diagnose it [7]. Novel tools for quantifying drug
induced platelet inhibition have brought into focus the
individual variations in antiplatelet responses. This
underscores the importance of identifying the optimal
antiplatelet drug protocol in order to achieve the tar-
geted level of anti-aggregation. Multiple electrode
aggregometry (MEA) has been shown to be a useful in-
strument in the quantification of platelet inhibition by
ASA [6]. Its mechanism of assessing platelet inhibition
is based on changes in impedance on its sensor wires
secondary to platelet adherence. Aspirin resistance has
been suggested to range anywhere from 1 to 45% [7].
The efficacy of ASA absorption, TXA2 independent
platelet activation pathways, COX-1 gene mutations, as
well as ASA interactions with other medications have
all been postulated to play a role in inducing aspirin re-
sistance [9]. The response to ASA should best be
viewed as a continuous variable. Dichotomizing patients
into responders or non-responders is, however, suitable
for scientific research and is commonly employed for this
purpose [7]. The presence of ASA low-responsiveness has
been linked to an increase in cardiovascular morbidity [9].
The clinical correlation of individual patient refractoriness
to ASA with an increased incidence of cardiovascular
complications is fundamental to the present study. This
will be, to the best of our knowledge, the first prospective
randomized study that will aim to evaluate whether the
combination of ASA and clopidogrel in ASA-resistant
CABG patients offers a clinical benefit. Our hypothesisthat a dual antiplatelet regime will improve patient out-
comes in this setting stems from the convergence of the
clinical impact of ASA resistance and the benefit gained




All consecutive patients aged 18 years or more, sched-
uled for an elective surgical myocardial revasculariza-
tion procedure using cardiopulmonary bypass over the
study period, at the University Hospital Center Zagreb,
will be screened for the study. Written informed con-
sent will be obtained from all patients prior to enrol-
ment into the study. The preoperative exclusion
criteria will include valvular pathology warranting sur-
gical correction, critical preoperative state, inability to
provide informed consent, reoperation, any medical con-
dition for which dual antiplatelet therapy is indicated,
redo-CABG, off-pump CABG, preoperative antiplatelet
therapy other than ASA or clopidogrel, preoperative
anticoagulation with coumadin and history of cerebro-
vascular accidents. Furthermore, patients who require
postoperative anticoagulation, intra-aortic balloon pump
support, or who die prior to postoperative day 4 will not
be included into the study. All other consecutive isolated
CABG patients will be screened for the study. Those
patients who exhibit aspirin resistance on their MEA
evaluation on postoperative day 4 will then be rando-
mized into two groups.
Ethics
The Ethics Committee of the University Hospital Cen-
ter Zagreb has evaluated and approved the conduct of
this study (No. 01/001/VG) on 23 June 2010. Ethical
standards in line with the Declaration of Helsinki in-
volving research on human subjects will be strictly
adhered to. This protocol complies with the CONSORT
guidelines [10].
Sample size
An exact binomial test power analysis was performed in
order to estimate the approximate sample size required
to test the null hypothesis. The minimum effect size was
10%. Accounting for a maximum estimated 10% loss to
follow-up, a total of 219 patients will be required to test
the null hypothesis with an α value of 0.05 and a power
of 0.8.
Aspirin low-responsiveness
The ASPI test evaluates cyclooxygenase-dependent
platelet aggregation (using arachidonic acid) that is sen-
sitive to aspirin. Our definition of low response to ASA
will be based upon our own published experience with
Figure 1 Flowchart detailing the screening algorithm for
patient recruitment, followed by subsequent randomization
into the aspirin monotherapy or dual antiplatelet therapy
groups. CABG, coronary artery bypass grafting; MEA, multiple
electrode aggregometry; ASPI, cyclooxygenase dependent platelet
aggregation, AUC, area under the curve; ASA, acetylsalicylic acid;
MACCE, major adverse cardiac and cerebrovascular events.
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of patients [11]. In brief, patients in the aforementioned
study were divided into quartiles with respect to their
ASA responsiveness, and those in whom the ASPI test
was greater than the 75th percentile of the entire cohort
(that is, area under the curve, AUC ≥ 30 units) were
defined as being ASA low-responders [11]. This defin-
ition has been corroborated by published data from
other sources [12-14].
Randomization of patients and interventional strategy
All post-CABG patients in whom none of the postopera-
tive exclusion criteria have occurred will undergo MEA
analysis on postoperative day 4. Patients found to have
evidence of ASA low-responsiveness, as defined by an
ASPI test≥ 30 AUC, will undergo randomization into ei-
ther the control group or the dual antiplatelet therapy
(dAPT) group. Assignment to either group will be per-
formed by random allocation using randomization soft-
ware [15]. Patients in the control group will continue to
receive 300 mg of ASA in accordance to our hospital’s
standard post-CABG antiplatelet management strategy.
Patients in the dAPT group will, conversely, be subjected
to augmentation of their antiplatelet regime by receiving
75 mg of clopidogrel in addition to the 300 mg of ASA.
A flowchart depicting the screening and randomization
protocols is shown in Figure 1.
Preoperative antiplatelet therapy management
Preoperative antiplatelet therapy is managed by the re-
ferring cardiologist. It almost uniformly consists of 100
mg of ASA and this is continued up to the day of sur-
gery. Some patients receive clopidogrel in addition to
ASA in the preoperative period. Clopidogrel will be dis-
continued 5 days prior to the scheduled revasculariza-
tion procedure. All patients included in the study will
have received antiplatelet therapy for no less than 14
days prior to enrolment.
Perioperative management
The perioperative management of study patients will
not deviate from our hospital’s standard preoperative
anesthetic regime, which includes diazepam and morphine
prior to induction of anesthesia. Endotracheal tube, urin-
ary catheter, radial artery and pulmonary artery catheters
will be inserted. Our protocol will consist of induction
and maintenance of anesthesia with midazolam, fentanyl
and pancuronium bromide. This will be complemented
with sevoflurane inhalation. The initial ventilator settings
will consist of a tidal volume of 8 ml/kg, and a respiratory
rate of 12 breaths per minute. Systemic heparinization
with a target-activated clotting time> 480 seconds will be
utilized, followed by full reversal with protamine after
decannulation. The cardiopulmonary circuit will includethe Medtronic Affinity Trillium membrane oxygenator,
venous reservoir and PVC tubing (Medtronic, Minneap-
olis, USA) and a Stoeckert III roller pump (Stoeckert,
Munich, Germany). The ascending aorta and right atrium
will be cannulated for cardiopulmonary bypass (CPB). The
CPB flow will approximate 2.4 L/min/m2. Every effort will
be made to maintain the mean systemic pressure during
CPB between 60 and 80 mmHg. Vasopressors will be used
as needed in order to achieve the target mean pressure.
The patient’s temperature will be allowed to drift down to
32 to 34°C. Myocardial protection will be based upon a
combination of antegrade and retrograde cardioplegia,
coupled with topical cooling. Both the coronary and the
proximal aortic anastomoses will be performed on an
arrested heart, during a single period of aortic cross-
clamping. Weaning from CPB will typically be performed
without inotropic support. In patients in whom the car-
diac index will remain below 2.2 L/min/m2, dobutamine
will be administered. Norepinephrine will be instituted if
dobutamine produces excessive vasodilatation. Escalation
of vasoactive support, if necessary, will include the
addition of another inotrope, an intra-aortic balloon pump
or mechanical circulatory assistance.
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blocker, a hydroxy-methyl-glutaryl-CoA reductase in-
hibitor and a diuretic. Electrolytes will be supplemented
as indicated. An ACE inhibitor will be instituted, as tol-
erated. Peptic ulcer prophylaxis will be universally
implemented, and continued for six weeks postopera-
tively. Non-steroidal anti-inflammatory drugs will gener-
ally not be administered in the early postoperative
period. The antiplatelet regime will be based upon the
previously mentioned randomization protocol.
Blood sampling
Blood samples for MEA measurements will be obtained
on postoperative day (POD) 4 via peripheral venipuncture.
The search for an ideal anticoagulant for blood samples
used for the quantification of platelet function is still on-
going. Heparin will be the anticoagulant used in the
present study [16,17]. Blood will be collected in 4 ml
heparin (Lithium Heparin 68 IU)-coated BD Vacutainer
plastic tubes. Routine laboratory evaluations will be per-
formed and recorded preoperatively and on POD 4. The
same person, who has no direct involvement in either
patient care or postoperative follow-up, will perform all
MEA measurements. Blood samples will be allowed to
rest for 30 minutes after blood withdrawal and MEA will
be performed subsequently.
Multiple electrode aggregometry (MEA)
Whole blood aggregability will be determined using a
new generation impedance aggregometer (MultiplateW
analyzer, Dynabyte Medical, Munich, Germany). The
method has been described in detail previously, and has
already been validated [18]. In brief, the principle under-
lying MEA is that platelets are non-thrombogenic in
their resting state, but have the potential to present mul-
tiple surface receptors when activated, which enables
them to attach to a variety of surfaces. The accumulation
of platelets on the Multiplate sensor wires will increase
the electrical resistance between them. This variability in
impedance, which is expressed in arbitrary AUC units, is
the MEA parameter with the highest diagnostic value
[18,19]. The analysis takes 3 minutes for incubation
and 6 minutes for the post-stimulation measurement.
Platelet aggregation was determined in response to
stimulation with arachidonic acid with a final concen-
tration of 0.5 mM (ASPI test designed to evaluate ASA
effect) and ADP with a final concentration of 6.4 μM
(ADP test designed to evaluate thienopyridines, that is,
clopidogrel).
Patient follow-up
Prospective collection of the follow-up data will be carried
out postoperatively via three bimonthly telephone inter-
views over the initial 6 months. Three surgical residentswill perform the acquisition of the follow-up data. The
telephone interview will be based upon a customized
questionnaire, which incorporates information critical to
the present study. Follow-up data will then be stored in a
central database. Patients in whom the interview revealed
equivocal information pertinent to the study will be asked
to consign their medical records for further review by a
cardiac surgeon and a cardiologist blinded to the study
protocol. In the case that the opinions of the two
reviewers differ, a third reviewer will offer an opinion,
which will then be considered definitive and will be stored
in the central database.
Outcome definitions
The primary clinical endpoint of the study will be the in-
cidence of major adverse cardiac and cerebrovascular
events (MACCE) in relation to two distinct antiplatelet
strategies (ASA monotherapy or dual antiplatelet ther-
apy) in patients found to be ASA-resistant. MACCE will
be defined as a composite endpoint consisting of all-
cause mortality, non-fatal myocardial infarction, cerebro-
vascular accident and cardiovascular rehospitalization.
The definition of perioperative and postoperative myo-
cardial infarction will be based upon published recom-
mendations of the Joint European Society of Cardiology/
American College of Cardiology Foundation/American
Heart Association/World Heart Federation Task Force
for the Redefinition of Myocardial Infarction [20]. The
definition of stroke will be based upon a new onset focal
neurological deficit lasting > 24 hours or an imaging
study suggestive of an acute clinically relevant cerebral
lesion in patients with rapid recovery [21].
Bleeding events will constitute the secondary clinical
endpoint. They will be stratified in accordance to the
consensus report from the Bleeding Academic Research
Consortium (BARC). In brief, the hemorrhagic compli-
cations according to the BARC scale range from type 1,
which denotes bleeding that is not actionable, to type 5
which is defined as a bleeding-related fatal event [22].
Type 0 denotes the absence of bleeding [22].
Statistical analysis
The continuous data will be presented as mean values ±
standard deviation (SD) or medians with their respective
interquartile range. Categorical variables will be pre-
sented as absolute numbers with percentages. Analyses
of continuous data between different groups of patients
will be performed using the Mann-Whitney U-test. Dif-
ferences between categorical variables will be evaluated
with Fisher’s exact test. A two-tailed P-value will be used
amd P < 0.05 will be considered significant for all
deployed statistical calculations. The data will be pro-
cessed using the Statistica 9 software package (StatSoft
Inc., Tulsa, USA).
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The disruption of the integrity of atherosclerotic lesions
followed by secondary thrombosis is recognized as the pri-
mary lesion responsible for a variety of acute ischemic
syndromes [9]. Continued improvement of surgical out-
comes in patients with coronary artery disease is the result
of a convergence of technical progress and better tailoring
of pharmacotherapy. The fundamental goal of this study is
to test the hypothesis that tailored modulation of platelet
activity based on reproducible laboratory measurements
of antiplatelet drug responses has the potential for im-
proving patient outcomes following CABG. Patients with
documented aspirin resistance early after CABG will be
randomized to receive either additional clopidogrel or no
augmentation of their anti-aggregation management. The
incidence of MACCE will be recorded, as well as the
safety profile in terms of bleeding events for both treat-
ment arms.
The design of this study is a prospective randomized
one. It will enrol consecutive cardiac surgical patients
based upon pre-specified criteria. The discriminatory vari-
able among the screened patients will be a reproducibly
quantifiable deficiency in their antiplatelet therapy re-
sponse. This will create a homogenous patient population,
allowing for a robust analysis. We believe that the adverse
impact of aspirin resistance on patient outcomes coupled
with its relative frequency add merit to a study such as
this. It is paramount, however, to objectively weigh the
hypothetical benefit of dual antiplatelet therapy against
the potentially increased susceptibility for bleeding. The
benefit of dual antiplatelet therapy has not been univer-
sally reproducible in all publications dealing with the sub-
ject. Kulik et al. have evaluated the effect of adding
clopidogrel to ASA on the degree of intimal hyperplasia in
saphenous vein coronary artery bypass grafts [23]. No sig-
nificant reduction in intimal hyperplasia was observed in
that study [23]. Conversely, Gao and coauthors documen-
ted superior venous graft patency with dual antiplatelet
therapy in comparison to ASA monotherapy [24]. Neither
of these studies explored the impact of interpatient vari-
ability to antiplatelet drug therapy on patient outcomes.
The strategy of adding a thienopyridine to patients who
have been found to be ASA resistant following CABG has
thus far been unexplored. The present trial is designed to
offer more information on that specific subject.
Should the results of this study prove to document su-
periority of the dual antiplatelet regime in patients found
to be aspirin resistant, this could promote an alteration
of the contemporary management of platelet inhibition
in patients undergoing CABG towards a more aggressive
approach.
Trial status
Patient recruitment for the study is currently ongoing.Abbreviations
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